Joan Besalduch

Palma, PM, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.

Journal: Annals of hematology
Published: August 29, 2016

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma.

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma.

Journal: OncoTargets and therapy
Published: November 25, 2014

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.

Journal: PloS one
Published: October 26, 2014

Fluorescence resonance energy transfer-based real-time polymerase chain reaction method without DNA extraction for the genotyping of F5, F2, F12, MTHFR, and HFE.

Fluorescence resonance energy transfer-based real-time polymerase chain reaction method without DNA extraction for the genotyping of F5, F2, F12, MTHFR, and HFE.

Journal: Journal of blood medicine
Published: July 17, 2014

Radiation therapy overcomes adverse prognostic role of cyclooxygenase-2 expression on Reed-Sternberg cells in early Hodgkin lymphoma.

Radiation therapy overcomes adverse prognostic role of cyclooxygenase-2 expression on Reed-Sternberg cells in early Hodgkin lymphoma.

Journal: International journal of radiation oncology, biology, physics
Published: July 03, 2014

Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.

Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.

Journal: Biomarker research
Published: June 27, 2014

xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies.

xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies.

Journal: OncoTargets and therapy
Published: June 25, 2014

Genetics of lymphocytes influences the emergence of second cancer in chronic lymphocytic leukemia.

Genetics of lymphocytes influences the emergence of second cancer in chronic lymphocytic leukemia.

Journal: Anticancer research
Published: April 30, 2014

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

Journal: British journal of haematology
Published: June 11, 2013

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Journal: Blood
Published: July 14, 2012

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.

Journal: Haematologica
Published: November 08, 2011

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Journal: Haematologica
Published: October 14, 2011
Showing 1-12 of 13

Last Updated: 09/26/2026